(19) World Intellectual Property Organization International Bureau

anization
ional Bureau
OMP





(43) International Publication Date 14 October 2004 (14.10.2004)

PCT

(10) International Publication Number WO 2004/087622 A3

(51) International Patent Classification⁷: 14/72

C07K 14/47,

(21) International Application Number:

PCT/EP2004/004132

(22) International Filing Date:

2 April 2004 (02.04.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 03290831.1

2 April 2003 (02.04.2003) EP


- (71) Applicant (for all designated States except US): IN-STITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE [FR/FR]; 101, rue de Tolbiac, F-75654 Paris Cedex 13 (FR).
- (71) Applicant (for all designated States except UA): UNI-VERSITE RENE DESCARTES PARIS V [FR/FR]; 12, rue de l'Ecole de Médecine, F-75270 Paris Cedex 06 (FR).
- (71) Applicant (for all designated States except US): UNI-VERSITE PARIS-SUD XI [FR/FR]; 15, rue Georges Clémenceau, F-91405 Orsay Cedex (FR).

- (72) Inventors; and
- (75) Inventors/Applicants (for US only): DE ROUX, Nicolas [FR/FR]; 128, rue Henri Litolff, F-92270 Bois-Colombes (FR). GENIN, Emmanuelle [FR/FR]; 3, rue Friant, F-75014 Paris (FR). MILGROM, Edwin [FR/FR]; 14, boulevard Colbert, F-92330 Sceaux (FR). CHAUSSAIN, Jean-Louis [FR/FR]; 11, rue Sédillot, F-75007 Paris (FR). CAREL, Jean-Claude [FR/FR]; 30, rue Saint James, F-92200 Neuilly sur Seine (FR).
- (74) Agent: CABINET HIRSCH; Groupement 161, 34, rue de Bassano, F-75008 Paris (FR).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

[Continued on next page]

(54) Title: GPR54 RECEPTOR AGONIST AND ANTAGONIST USEFUL FOR THE TREATMENTT OF GONADOTROPIN RELATED DISEASES

Family 1



(57) Abstract: The invention provides an agonist or antagonist of the GPR54 receptor for its use for treating a gonadotropin related disorder, a ligand of the GPR54 receptor for its use for diagnosing a subject's gonadotropin abnormality; a method for screening a compound that affect the gonadotropic axis comprising the step of assaying the compound in the presence of a GPR54 receptor and novel proteins useful in the above.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i)) for all designations
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,

ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 18 November 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

International Application No FET/EP2004/004132

	·	04/004132		
A. CLASSII IPC 7	FICATION OF SUBJECT MATTER CO7K14/47 CO7K14/72	# W	-	
According to	International Patent Classification (IPC) or to both national classificat	lion and IPC		
B. FIELDS	SEARCHED			
Minimum do IPC 7	cumentation searched (classification system followed by classificatio CO7K	n symbols)		
	ion searched other than minimum documentation to the extent that su			
	ata base consulted during the international search (name of data bas ternal, MEDLINE, BIOSIS, WPI Data, P			
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT			
Category *	Citation of document, with indication, where appropriate, of the rele	Relevant to daim No.		
X	EP 1 126 028 A (TAKEDA CHEMICAL ILTD) 22 August 2001 (2001-08-22) cited in the application paragraphs '0016!, '0017!, '014' '0253!, '0313!, '0325!	1-12, 21-25		
X	WO 03/003983 A (QUAN YONG ;SMITH (US); BOROWSKY BETH E (US); SYNAP 16 January 2003 (2003-01-16) cited in the application pages 9-12	1-12, 21-25		
	_	/		
X Furt	her documents are listed in the continuation of box C.	χ Patent family members are listed	in annex.	
'A' docume consider tiling of the citation of the country that is a citation of the citation o	ant defining the general state of the art which is not dered to be of particular relevance document but published on or after the international date and which may throw doubts on priority claim(s) or is cited to establish the publication date of another nor other special reason (as specified) ent referring to an oral disclosure, use, exhibition or means	PT later document published after the integration or priority date and not in conflict with cited to understand the principle or the invention. "X" document of particular relevance; the cannot be considered novel or cannot involve an inventive step when the document of particular relevance; the cannot be considered to involve an in document is combined with one or ments, such combination being obvious the art. "&" document member of the same patent	the application but early underlying the claimed invention to be considered to current is taken alone claimed invention ventive step when the pre other such docu-us to a person skilled	
Date of the	actual completion of the international search	Date of mailing of the international sea	arch report	
8	September 2004	06/10/2004		

Authorized officer

Mabit, H

European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016

Name and mailing address of the ISA

International Application No PCI / EP2004/004132

		Fe1/EP2004/004132
C{Continu	etion) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Retevant to claim No.
Ρ,Χ	DE ROUX NICOLAS ET AL: "Hypogonadotropic hypogonadism due to loss of function of the K1SS1-derived peptide receptor GPR54." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. UNITED STATES 16 SEP 2003, vol. 100, no. 19, 16 September 2003 (2003-09-16), pages 10972-10976, XP002262289 ISSN: 0027-8424 page 10975, paragraph DISCUSSION -& DATABASE NCBI 23 August 2004 (2004-08-23), "G protein-coupled receptor 54" XP002295361 retrieved from NCBI Database accession no. NM_032551 the whole document	1-28
Ρ,Χ	SEMINARA STEPHANIE B ET AL: "The GPR54 gene as a regulator of puberty." NEW ENGLAND JOURNAL OF MEDICINE, vol. 349, no. 17, 23 October 2003 (2003-10-23), pages 1614-1627, XP009021628 ISSN: 0028-4793 (ISSN print) page 1622, column 2, paragraph DISCUSSION - page 1626, column 2	1-28
Α	KOTANI MASATO ET AL: "The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 37, 14 September 2001 (2001-09-14), pages 34631-34636, XP002262291 ISSN: 0021-9258 cited in the application	
A	US 5 750 366 A (SEALFON STUART C) 12 May 1998 (1998-05-12)	

ternational application No. PCT/EP2004/004132

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2. X Claims Nos.: 1-12, 21-26, and 28 partially because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically: see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this international Search Report covers all searchable claims.
As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.2

Claims Nos.: 1-12, 21-26, and 28 partially

Present claims 1-12, 21-26, and 28 partially relate to products defined by reference to a desirable characteristic or property, namely to be agonist, antagonist or ligand of the GPR54 receptor. The claims cover all products having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such products. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the products by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely the subject-matter of claims 1-12, 21-26, and 28 partially in relation to the agonist kiss-1 and the corresponding functional truncation of kiss-1, i.e. the decapeptide 45-54 (dependent claim 27).

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

information on patent family members

International Application No Fee / EP2004/004132

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
EP 1126028	A	22-08-2001	JP	2000312590 A	14-11-2000
• • • • • • • • • • • • • • • • • • • •			AU	6230699 A	15-05-2000
			BR	9914835 A	18-06-2002
			CA	2347294 A1	04-05-2000
			EP	1126028 A1	22-08-2001
			HU	0104937 A2	29-04-2002
			NO	20012059 A	26-06-2001
			NZ	510977 A	25-10-2002
			SK	5502001 A3	07-01-2002
			US	6699965 B1	02-03-2004
			CN	1324405 T	28-11-2001
			CZ	20011358 A3	15-08-2001
			ID	28288 A	10-05-2001
			WO	0024890 A1	04-05-2000
			PL	347553 A1	08-04-2002
			ZA	200103152 A	19-10-2001
WO 03003983	A	16-01-2003	US	2002077469 A1	20-06-2002
			WO	03003983 A2	16-01-2003
			US	2003022839 A1	30-01-2003
US 5750366		12-05-1998	AU	4542793 A	24-01-1994
	••	32 00 000	CA	2138999 A1	06-01-1994
			EP	0647275 A1	12-04-1995
•			JP	7509601 T	26-10-1995
			WO	9400590 A1	06-01-1994
			US	5985583 A	16-11-1999